Bax/Mcl-1 balance affects neutrophil survival in intermittent hypoxia and obstructive sleep apnea: effects of p38MAPK and ERK1/2 signaling
Prolonged neutrophil survival is evident in various cardiovascular and respiratory morbidities, in hypoxic conditions in-vitro and in patients with obstructive sleep apnea (OSA) characterized by nightly intermittent hypoxia (IH). This may lead to persistent inflammation, tissue injury and dysfunctio...
Saved in:
| Published in | Journal of translational medicine Vol. 10; no. 1; p. 211 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
22.10.2012
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1479-5876 1479-5876 |
| DOI | 10.1186/1479-5876-10-211 |
Cover
Loading…
| Abstract | Prolonged neutrophil survival is evident in various cardiovascular and respiratory morbidities, in hypoxic conditions in-vitro and in patients with obstructive sleep apnea (OSA) characterized by nightly intermittent hypoxia (IH). This may lead to persistent inflammation, tissue injury and dysfunction. We therefore investigated by a translational approach the potential contribution of the intrinsic stress-induced mitochondrial pathway in extending neutrophil survival under IH conditions. Thus, neutrophils of healthy individuals treated with IH in-vitro and neutrophils of OSA patients undergoing nightly IH episodes in-vivo were investigated. Specifically, the balance between pro-apoptotic Bax and anti-apoptotic Mcl-1 protein expression, and the potential involvement of p38MAPK and ERK1/2 signaling pathways in the control of Mcl-1 expression were investigated.
Purified neutrophils were exposed to IH and compared to normoxia and to sustained hypoxia (SH) using a BioSpherix-OxyCycler C42 system. Bax and Mcl-1 levels, and p38MAPK and ERK1/2 phosphorylation were determined by western blotting. Also, Bax/Mcl-1 expression and Bax translocation to the mitochondria were assessed by confocal microscopy in pre-apoptotic neutrophils, before the appearance of apoptotic morphology. Co-localization of Bax and mitochondria was quantified by LSM 510 CarlZeiss MicroImaging using Manders Overlap Coefficient. A paired two-tailed t test, with Bonferroni correction for multiple comparisons, was used for statistical analysis.
Compared to normoxia, IH and SH up-regulated the anti-apoptotic Mcl-1 by about 2-fold, down-regulated the pro-apoptotic Bax by 41% and 27%, respectively, and inhibited Bax co-localization with mitochondria before visible morphological signs of apoptosis were noted. IH induced ERK1/2 and p38MAPKs phosphorylation, whereas SH induced only p38MAPK phosphorylation. Accordingly, both ERK and p38MAPK inhibitors attenuated the IH-induced Mcl-1 increase. In SH, only p38MAPK inhibition decreased Mcl-1 expression. Similar to neutrophils of healthy subjects exposed to IH (0.97± 0.2), in OSA neutrophils, Bax/Mcl-1 ratio was significantly lower compared to normoxic controls (1.0±0.5 vs.1.99±0.3, p=0.015), and Bax did not co-localize with mitochondria.
These findings suggest that decreased Bax/Mcl-1 balance promotes neutrophil survival in IH in-vitro as well as in OSA patients. Moreover, Bax/Mcl-1 protein function in IH and SH might be regulated by different signal transduction pathways, highlighting a novel regulatory function through ERK1/2 signaling in IH. |
|---|---|
| AbstractList | Prolonged neutrophil survival is evident in various cardiovascular and respiratory morbidities, in hypoxic conditions in-vitro and in patients with obstructive sleep apnea (OSA) characterized by nightly intermittent hypoxia (IH). This may lead to persistent inflammation, tissue injury and dysfunction. We therefore investigated by a translational approach the potential contribution of the intrinsic stress-induced mitochondrial pathway in extending neutrophil survival under IH conditions. Thus, neutrophils of healthy individuals treated with IH in-vitro and neutrophils of OSA patients undergoing nightly IH episodes in-vivo were investigated. Specifically, the balance between pro-apoptotic Bax and anti-apoptotic Mcl-1 protein expression, and the potential involvement of p38MAPK and ERK1/2 signaling pathways in the control of Mcl-1 expression were investigated. Purified neutrophils were exposed to IH and compared to normoxia and to sustained hypoxia (SH) using a BioSpherix-OxyCycler C42 system. Bax and Mcl-1 levels, and p38MAPK and ERK1/2 phosphorylation were determined by western blotting. Also, Bax/Mcl-1 expression and Bax translocation to the mitochondria were assessed by confocal microscopy in pre-apoptotic neutrophils, before the appearance of apoptotic morphology. Co-localization of Bax and mitochondria was quantified by LSM 510 CarlZeiss MicroImaging using Manders Overlap Coefficient. A paired two-tailed t test, with Bonferroni correction for multiple comparisons, was used for statistical analysis. Compared to normoxia, IH and SH up-regulated the anti-apoptotic Mcl-1 by about 2-fold, down-regulated the pro-apoptotic Bax by 41% and 27%, respectively, and inhibited Bax co-localization with mitochondria before visible morphological signs of apoptosis were noted. IH induced ERK1/2 and p38MAPKs phosphorylation, whereas SH induced only p38MAPK phosphorylation. Accordingly, both ERK and p38MAPK inhibitors attenuated the IH-induced Mcl-1 increase. In SH, only p38MAPK inhibition decreased Mcl-1 expression. Similar to neutrophils of healthy subjects exposed to IH (0.97[+ or -] 0.2), in OSA neutrophils, Bax/Mcl-1 ratio was significantly lower compared to normoxic controls (1.0[+ or -]0.5 vs.1.99[+ or -]0.3, p=0.015), and Bax did not co-localize with mitochondria. These findings suggest that decreased Bax/Mcl-1 balance promotes neutrophil survival in IH in-vitro as well as in OSA patients. Moreover, Bax/Mcl-1 protein function in IH and SH might be regulated by different signal transduction pathways, highlighting a novel regulatory function through ERK1/2 signaling in IH. Background: Prolonged neutrophil survival is evident in various cardiovascular and respiratory morbidities, in hypoxic conditions in-vitro and in patients with obstructive sleep apnea (OSA) characterized by nightly intermittent hypoxia (IH). This may lead to persistent inflammation, tissue injury and dysfunction. We therefore investigated by a translational approach the potential contribution of the intrinsic stress-induced mitochondrial pathway in extending neutrophil survival under IH conditions. Thus, neutrophils of healthy individuals treated with IH in-vitro and neutrophils of OSA patients undergoing nightly IH episodes in-vivo were investigated. Specifically, the balance between pro-apoptotic Bax and anti-apoptotic Mcl-1 protein expression, and the potential involvement of p38MAPK and ERK1/2 signaling pathways in the control of Mcl-1 expression were investigated. Methods: Purified neutrophils were exposed to IH and compared to normoxia and to sustained hypoxia (SH) using a BioSpherix-OxyCycler C42 system. Bax and Mcl-1 levels, and p38MAPK and ERK1/2 phosphorylation were determined by western blotting. Also, Bax/Mcl-1 expression and Bax translocation to the mitochondria were assessed by confocal microscopy in pre-apoptotic neutrophils, before the appearance of apoptotic morphology. Co-localization of Bax and mitochondria was quantified by LSM 510 CarlZeiss MicroImaging using Manders Overlap Coefficient. A paired two-tailed t test, with Bonferroni correction for multiple comparisons, was used for statistical analysis. Results: Compared to normoxia, IH and SH up-regulated the anti-apoptotic Mcl-1 by about 2-fold, down-regulated the pro-apoptotic Bax by 41% and 27%, respectively, and inhibited Bax co-localization with mitochondria before visible morphological signs of apoptosis were noted. IH induced ERK1/2 and p38MAPKs phosphorylation, whereas SH induced only p38MAPK phosphorylation. Accordingly, both ERK and p38MAPK inhibitors attenuated the IH-induced Mcl-1 increase. In SH, only p38MAPK inhibition decreased Mcl-1 expression. Similar to neutrophils of healthy subjects exposed to IH (0.97 plus or minus 0.2), in OSA neutrophils, Bax/Mcl-1 ratio was significantly lower compared to normoxic controls (1.0 plus or minus 0.5 vs.1.99 plus or minus 0.3, p=0.015), and Bax did not co-localize with mitochondria. Conclusions: These findings suggest that decreased Bax/Mcl-1 balance promotes neutrophil survival in IH in-vitro as well as in OSA patients. Moreover, Bax/Mcl-1 protein function in IH and SH might be regulated by different signal transduction pathways, highlighting a novel regulatory function through ERK1/2 signaling in IH. BACKGROUND: Prolonged neutrophil survival is evident in various cardiovascular and respiratory morbidities, in hypoxic conditions in-vitro and in patients with obstructive sleep apnea (OSA) characterized by nightly intermittent hypoxia (IH). This may lead to persistent inflammation, tissue injury and dysfunction. We therefore investigated by a translational approach the potential contribution of the intrinsic stress-induced mitochondrial pathway in extending neutrophil survival under IH conditions. Thus, neutrophils of healthy individuals treated with IH in-vitro and neutrophils of OSA patients undergoing nightly IH episodes in-vivo were investigated. Specifically, the balance between pro-apoptotic Bax and anti-apoptotic Mcl-1 protein expression, and the potential involvement of p38MAPK and ERK1/2 signaling pathways in the control of Mcl-1 expression were investigated. METHODS: Purified neutrophils were exposed to IH and compared to normoxia and to sustained hypoxia (SH) using a BioSpherix-OxyCycler C42 system. Bax and Mcl-1 levels, and p38MAPK and ERK1/2 phosphorylation were determined by western blotting. Also, Bax/Mcl-1 expression and Bax translocation to the mitochondria were assessed by confocal microscopy in pre-apoptotic neutrophils, before the appearance of apoptotic morphology. Co-localization of Bax and mitochondria was quantified by LSM 510 CarlZeiss MicroImaging using Manders Overlap Coefficient. A paired two-tailed t test, with Bonferroni correction for multiple comparisons, was used for statistical analysis. RESULTS: Compared to normoxia, IH and SH up-regulated the anti-apoptotic Mcl-1 by about 2-fold, down-regulated the pro-apoptotic Bax by 41% and 27%, respectively, and inhibited Bax co-localization with mitochondria before visible morphological signs of apoptosis were noted. IH induced ERK1/2 and p38MAPKs phosphorylation, whereas SH induced only p38MAPK phosphorylation. Accordingly, both ERK and p38MAPK inhibitors attenuated the IH-induced Mcl-1 increase. In SH, only p38MAPK inhibition decreased Mcl-1 expression. Similar to neutrophils of healthy subjects exposed to IH (0.97± 0.2), in OSA neutrophils, Bax/Mcl-1 ratio was significantly lower compared to normoxic controls (1.0±0.5 vs.1.99±0.3, p=0.015), and Bax did not co-localize with mitochondria. CONCLUSIONS: These findings suggest that decreased Bax/Mcl-1 balance promotes neutrophil survival in IH in-vitro as well as in OSA patients. Moreover, Bax/Mcl-1 protein function in IH and SH might be regulated by different signal transduction pathways, highlighting a novel regulatory function through ERK1/2 signaling in IH. Prolonged neutrophil survival is evident in various cardiovascular and respiratory morbidities, in hypoxic conditions in-vitro and in patients with obstructive sleep apnea (OSA) characterized by nightly intermittent hypoxia (IH). This may lead to persistent inflammation, tissue injury and dysfunction. We therefore investigated by a translational approach the potential contribution of the intrinsic stress-induced mitochondrial pathway in extending neutrophil survival under IH conditions. Thus, neutrophils of healthy individuals treated with IH in-vitro and neutrophils of OSA patients undergoing nightly IH episodes in-vivo were investigated. Specifically, the balance between pro-apoptotic Bax and anti-apoptotic Mcl-1 protein expression, and the potential involvement of p38MAPK and ERK1/2 signaling pathways in the control of Mcl-1 expression were investigated. Purified neutrophils were exposed to IH and compared to normoxia and to sustained hypoxia (SH) using a BioSpherix-OxyCycler C42 system. Bax and Mcl-1 levels, and p38MAPK and ERK1/2 phosphorylation were determined by western blotting. Also, Bax/Mcl-1 expression and Bax translocation to the mitochondria were assessed by confocal microscopy in pre-apoptotic neutrophils, before the appearance of apoptotic morphology. Co-localization of Bax and mitochondria was quantified by LSM 510 CarlZeiss MicroImaging using Manders Overlap Coefficient. A paired two-tailed t test, with Bonferroni correction for multiple comparisons, was used for statistical analysis. Compared to normoxia, IH and SH up-regulated the anti-apoptotic Mcl-1 by about 2-fold, down-regulated the pro-apoptotic Bax by 41% and 27%, respectively, and inhibited Bax co-localization with mitochondria before visible morphological signs of apoptosis were noted. IH induced ERK1/2 and p38MAPKs phosphorylation, whereas SH induced only p38MAPK phosphorylation. Accordingly, both ERK and p38MAPK inhibitors attenuated the IH-induced Mcl-1 increase. In SH, only p38MAPK inhibition decreased Mcl-1 expression. Similar to neutrophils of healthy subjects exposed to IH (0.97± 0.2), in OSA neutrophils, Bax/Mcl-1 ratio was significantly lower compared to normoxic controls (1.0±0.5 vs.1.99±0.3, p=0.015), and Bax did not co-localize with mitochondria. These findings suggest that decreased Bax/Mcl-1 balance promotes neutrophil survival in IH in-vitro as well as in OSA patients. Moreover, Bax/Mcl-1 protein function in IH and SH might be regulated by different signal transduction pathways, highlighting a novel regulatory function through ERK1/2 signaling in IH. Prolonged neutrophil survival is evident in various cardiovascular and respiratory morbidities, in hypoxic conditions in-vitro and in patients with obstructive sleep apnea (OSA) characterized by nightly intermittent hypoxia (IH). This may lead to persistent inflammation, tissue injury and dysfunction. We therefore investigated by a translational approach the potential contribution of the intrinsic stress-induced mitochondrial pathway in extending neutrophil survival under IH conditions. Thus, neutrophils of healthy individuals treated with IH in-vitro and neutrophils of OSA patients undergoing nightly IH episodes in-vivo were investigated. Specifically, the balance between pro-apoptotic Bax and anti-apoptotic Mcl-1 protein expression, and the potential involvement of p38MAPK and ERK1/2 signaling pathways in the control of Mcl-1 expression were investigated.BACKGROUNDProlonged neutrophil survival is evident in various cardiovascular and respiratory morbidities, in hypoxic conditions in-vitro and in patients with obstructive sleep apnea (OSA) characterized by nightly intermittent hypoxia (IH). This may lead to persistent inflammation, tissue injury and dysfunction. We therefore investigated by a translational approach the potential contribution of the intrinsic stress-induced mitochondrial pathway in extending neutrophil survival under IH conditions. Thus, neutrophils of healthy individuals treated with IH in-vitro and neutrophils of OSA patients undergoing nightly IH episodes in-vivo were investigated. Specifically, the balance between pro-apoptotic Bax and anti-apoptotic Mcl-1 protein expression, and the potential involvement of p38MAPK and ERK1/2 signaling pathways in the control of Mcl-1 expression were investigated.Purified neutrophils were exposed to IH and compared to normoxia and to sustained hypoxia (SH) using a BioSpherix-OxyCycler C42 system. Bax and Mcl-1 levels, and p38MAPK and ERK1/2 phosphorylation were determined by western blotting. Also, Bax/Mcl-1 expression and Bax translocation to the mitochondria were assessed by confocal microscopy in pre-apoptotic neutrophils, before the appearance of apoptotic morphology. Co-localization of Bax and mitochondria was quantified by LSM 510 CarlZeiss MicroImaging using Manders Overlap Coefficient. A paired two-tailed t test, with Bonferroni correction for multiple comparisons, was used for statistical analysis.METHODSPurified neutrophils were exposed to IH and compared to normoxia and to sustained hypoxia (SH) using a BioSpherix-OxyCycler C42 system. Bax and Mcl-1 levels, and p38MAPK and ERK1/2 phosphorylation were determined by western blotting. Also, Bax/Mcl-1 expression and Bax translocation to the mitochondria were assessed by confocal microscopy in pre-apoptotic neutrophils, before the appearance of apoptotic morphology. Co-localization of Bax and mitochondria was quantified by LSM 510 CarlZeiss MicroImaging using Manders Overlap Coefficient. A paired two-tailed t test, with Bonferroni correction for multiple comparisons, was used for statistical analysis.Compared to normoxia, IH and SH up-regulated the anti-apoptotic Mcl-1 by about 2-fold, down-regulated the pro-apoptotic Bax by 41% and 27%, respectively, and inhibited Bax co-localization with mitochondria before visible morphological signs of apoptosis were noted. IH induced ERK1/2 and p38MAPKs phosphorylation, whereas SH induced only p38MAPK phosphorylation. Accordingly, both ERK and p38MAPK inhibitors attenuated the IH-induced Mcl-1 increase. In SH, only p38MAPK inhibition decreased Mcl-1 expression. Similar to neutrophils of healthy subjects exposed to IH (0.97± 0.2), in OSA neutrophils, Bax/Mcl-1 ratio was significantly lower compared to normoxic controls (1.0±0.5 vs.1.99±0.3, p=0.015), and Bax did not co-localize with mitochondria.RESULTSCompared to normoxia, IH and SH up-regulated the anti-apoptotic Mcl-1 by about 2-fold, down-regulated the pro-apoptotic Bax by 41% and 27%, respectively, and inhibited Bax co-localization with mitochondria before visible morphological signs of apoptosis were noted. IH induced ERK1/2 and p38MAPKs phosphorylation, whereas SH induced only p38MAPK phosphorylation. Accordingly, both ERK and p38MAPK inhibitors attenuated the IH-induced Mcl-1 increase. In SH, only p38MAPK inhibition decreased Mcl-1 expression. Similar to neutrophils of healthy subjects exposed to IH (0.97± 0.2), in OSA neutrophils, Bax/Mcl-1 ratio was significantly lower compared to normoxic controls (1.0±0.5 vs.1.99±0.3, p=0.015), and Bax did not co-localize with mitochondria.These findings suggest that decreased Bax/Mcl-1 balance promotes neutrophil survival in IH in-vitro as well as in OSA patients. Moreover, Bax/Mcl-1 protein function in IH and SH might be regulated by different signal transduction pathways, highlighting a novel regulatory function through ERK1/2 signaling in IH.CONCLUSIONSThese findings suggest that decreased Bax/Mcl-1 balance promotes neutrophil survival in IH in-vitro as well as in OSA patients. Moreover, Bax/Mcl-1 protein function in IH and SH might be regulated by different signal transduction pathways, highlighting a novel regulatory function through ERK1/2 signaling in IH. Doc number: 211 Abstract Background: Prolonged neutrophil survival is evident in various cardiovascular and respiratory morbidities, in hypoxic conditions in-vitro and in patients with obstructive sleep apnea (OSA) characterized by nightly intermittent hypoxia (IH). This may lead to persistent inflammation, tissue injury and dysfunction. We therefore investigated by a translational approach the potential contribution of the intrinsic stress-induced mitochondrial pathway in extending neutrophil survival under IH conditions. Thus, neutrophils of healthy individuals treated with IH in-vitro and neutrophils of OSA patients undergoing nightly IH episodes in-vivo were investigated. Specifically, the balance between pro-apoptotic Bax and anti-apoptotic Mcl-1 protein expression, and the potential involvement of p38MAPK and ERK1/2 signaling pathways in the control of Mcl-1 expression were investigated. Methods: Purified neutrophils were exposed to IH and compared to normoxia and to sustained hypoxia (SH) using a BioSpherix-OxyCycler C42 system. Bax and Mcl-1 levels, and p38MAPK and ERK1/2 phosphorylation were determined by western blotting. Also, Bax/Mcl-1 expression and Bax translocation to the mitochondria were assessed by confocal microscopy in pre-apoptotic neutrophils, before the appearance of apoptotic morphology. Co-localization of Bax and mitochondria was quantified by LSM 510 CarlZeiss MicroImaging using Manders Overlap Coefficient. A paired two-tailed t test, with Bonferroni correction for multiple comparisons, was used for statistical analysis. Results: Compared to normoxia, IH and SH up-regulated the anti-apoptotic Mcl-1 by about 2-fold, down-regulated the pro-apoptotic Bax by 41% and 27%, respectively, and inhibited Bax co-localization with mitochondria before visible morphological signs of apoptosis were noted. IH induced ERK1/2 and p38MAPKs phosphorylation, whereas SH induced only p38MAPK phosphorylation. Accordingly, both ERK and p38MAPK inhibitors attenuated the IH-induced Mcl-1 increase. In SH, only p38MAPK inhibition decreased Mcl-1 expression. Similar to neutrophils of healthy subjects exposed to IH (0.97± 0.2), in OSA neutrophils, Bax/Mcl-1 ratio was significantly lower compared to normoxic controls (1.0±0.5 vs.1.99±0.3, p=0.015), and Bax did not co-localize with mitochondria. Conclusions: These findings suggest that decreased Bax/Mcl-1 balance promotes neutrophil survival in IH in-vitro as well as in OSA patients. Moreover, Bax/Mcl-1 protein function in IH and SH might be regulated by different signal transduction pathways, highlighting a novel regulatory function through ERK1/2 signaling in IH. Abstract Background Prolonged neutrophil survival is evident in various cardiovascular and respiratory morbidities, in hypoxic conditions in-vitro and in patients with obstructive sleep apnea (OSA) characterized by nightly intermittent hypoxia (IH). This may lead to persistent inflammation, tissue injury and dysfunction. We therefore investigated by a translational approach the potential contribution of the intrinsic stress-induced mitochondrial pathway in extending neutrophil survival under IH conditions. Thus, neutrophils of healthy individuals treated with IH in-vitro and neutrophils of OSA patients undergoing nightly IH episodes in-vivo were investigated. Specifically, the balance between pro-apoptotic Bax and anti-apoptotic Mcl-1 protein expression, and the potential involvement of p38MAPK and ERK1/2 signaling pathways in the control of Mcl-1 expression were investigated. Methods Purified neutrophils were exposed to IH and compared to normoxia and to sustained hypoxia (SH) using a BioSpherix-OxyCycler C42 system. Bax and Mcl-1 levels, and p38MAPK and ERK1/2 phosphorylation were determined by western blotting. Also, Bax/Mcl-1 expression and Bax translocation to the mitochondria were assessed by confocal microscopy in pre-apoptotic neutrophils, before the appearance of apoptotic morphology. Co-localization of Bax and mitochondria was quantified by LSM 510 CarlZeiss MicroImaging using Manders Overlap Coefficient. A paired two-tailed t test, with Bonferroni correction for multiple comparisons, was used for statistical analysis. Results Compared to normoxia, IH and SH up-regulated the anti-apoptotic Mcl-1 by about 2-fold, down-regulated the pro-apoptotic Bax by 41% and 27%, respectively, and inhibited Bax co-localization with mitochondria before visible morphological signs of apoptosis were noted. IH induced ERK1/2 and p38MAPKs phosphorylation, whereas SH induced only p38MAPK phosphorylation. Accordingly, both ERK and p38MAPK inhibitors attenuated the IH-induced Mcl-1 increase. In SH, only p38MAPK inhibition decreased Mcl-1 expression. Similar to neutrophils of healthy subjects exposed to IH (0.97± 0.2), in OSA neutrophils, Bax/Mcl-1 ratio was significantly lower compared to normoxic controls (1.0±0.5 vs.1.99±0.3, p=0.015), and Bax did not co-localize with mitochondria. Conclusions These findings suggest that decreased Bax/Mcl-1 balance promotes neutrophil survival in IH in-vitro as well as in OSA patients. Moreover, Bax/Mcl-1 protein function in IH and SH might be regulated by different signal transduction pathways, highlighting a novel regulatory function through ERK1/2 signaling in IH. Background Prolonged neutrophil survival is evident in various cardiovascular and respiratory morbidities, in hypoxic conditions in-vitro and in patients with obstructive sleep apnea (OSA) characterized by nightly intermittent hypoxia (IH). This may lead to persistent inflammation, tissue injury and dysfunction. We therefore investigated by a translational approach the potential contribution of the intrinsic stress-induced mitochondrial pathway in extending neutrophil survival under IH conditions. Thus, neutrophils of healthy individuals treated with IH in-vitro and neutrophils of OSA patients undergoing nightly IH episodes in-vivo were investigated. Specifically, the balance between pro-apoptotic Bax and anti-apoptotic Mcl-1 protein expression, and the potential involvement of p38MAPK and ERK1/2 signaling pathways in the control of Mcl-1 expression were investigated. Methods Purified neutrophils were exposed to IH and compared to normoxia and to sustained hypoxia (SH) using a BioSpherix-OxyCycler C42 system. Bax and Mcl-1 levels, and p38MAPK and ERK1/2 phosphorylation were determined by western blotting. Also, Bax/Mcl-1 expression and Bax translocation to the mitochondria were assessed by confocal microscopy in pre-apoptotic neutrophils, before the appearance of apoptotic morphology. Co-localization of Bax and mitochondria was quantified by LSM 510 CarlZeiss MicroImaging using Manders Overlap Coefficient. A paired two-tailed t test, with Bonferroni correction for multiple comparisons, was used for statistical analysis. Results Compared to normoxia, IH and SH up-regulated the anti-apoptotic Mcl-1 by about 2-fold, down-regulated the pro-apoptotic Bax by 41% and 27%, respectively, and inhibited Bax co-localization with mitochondria before visible morphological signs of apoptosis were noted. IH induced ERK1/2 and p38MAPKs phosphorylation, whereas SH induced only p38MAPK phosphorylation. Accordingly, both ERK and p38MAPK inhibitors attenuated the IH-induced Mcl-1 increase. In SH, only p38MAPK inhibition decreased Mcl-1 expression. Similar to neutrophils of healthy subjects exposed to IH (0.97[+ or -] 0.2), in OSA neutrophils, Bax/Mcl-1 ratio was significantly lower compared to normoxic controls (1.0[+ or -]0.5 vs.1.99[+ or -]0.3, p=0.015), and Bax did not co-localize with mitochondria. Conclusions These findings suggest that decreased Bax/Mcl-1 balance promotes neutrophil survival in IH in-vitro as well as in OSA patients. Moreover, Bax/Mcl-1 protein function in IH and SH might be regulated by different signal transduction pathways, highlighting a novel regulatory function through ERK1/2 signaling in IH. Keywords: Intermittent hypoxia, Obstructive Sleep Apnea, Neutrophil mitochondrial apoptotic pathway, Bax/Mcl-1 balance, ERK 1/2 signaling, p38MAPK signaling |
| ArticleNumber | 211 |
| Audience | Academic |
| Author | Dyugovskaya, Larissa Polyakov, Andrey Lavie, Lena Cohen-Kaplan, Victoria Lavie, Peretz |
| AuthorAffiliation | 3 Unit of Anatomy and Cell Biology, The Ruth and Bruce Rappaport Faculty of Medicine, Technion, POB 9649, Haifa, 31096, Israel 1 The Lloyd Rigler Sleep Apnea Research Laboratory, The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel 2 Cancer and Vascular Biology Research Center, The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel |
| AuthorAffiliation_xml | – name: 2 Cancer and Vascular Biology Research Center, The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel – name: 3 Unit of Anatomy and Cell Biology, The Ruth and Bruce Rappaport Faculty of Medicine, Technion, POB 9649, Haifa, 31096, Israel – name: 1 The Lloyd Rigler Sleep Apnea Research Laboratory, The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel |
| Author_xml | – sequence: 1 givenname: Larissa surname: Dyugovskaya fullname: Dyugovskaya, Larissa – sequence: 2 givenname: Andrey surname: Polyakov fullname: Polyakov, Andrey – sequence: 3 givenname: Victoria surname: Cohen-Kaplan fullname: Cohen-Kaplan, Victoria – sequence: 4 givenname: Peretz surname: Lavie fullname: Lavie, Peretz – sequence: 5 givenname: Lena surname: Lavie fullname: Lavie, Lena |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23088735$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFk0tr3DAUhU1JaR7tvqsi6KYbZyTZsuUuCtMhbUMSWkq7FrIeMwq25EjykPyF_urKmUmaCQnFBourcz8u51wfZnvWWZVlbxE8RohWM1TWTU5oXeUI5hihF9nBfWnvwXk_OwzhEkJckrJ5le3jAlJaF-Qg-_OZX88uRJcj0PKOW6EA11qJGIBVY_RuWJkOhNGvzZp3wNj0RuV7E6OyEaxuBndtOOBWAteG6EcRzVqB0Ck1AD5YxT8CtQU6DYaCXsx_nN3qT36eoRkGwSwt74xdvs5eat4F9Wb7Pcp-fzn5tfiWn3__erqYn-dtjaqYU0EpgrIhVYEb2SLU8FYnMyqEW0jaVkoodUl4U9U4KYSCWFRQqUYXECski6PsdMOVjl-ywZue-xvmuGG3BeeXjPtoRKcYwhRDRCRBtShpU1OCBakSRuq6LYVOrE8b1jC2vZIieeJ5twPdvbFmxZZuzQpSFpiiBFhsAK1xzwB2b4Tr2ZQrm3JlCLIUe6J82I7h3dWoQmS9CUJ1KVDlxsBQgUiVnML0_1Kc9gLWTdEk6ftH0ks3-hTWpKpoXZKG0n-qJU-OGatdmlNMUDYnRYkpLMtpwuMnVOmRqjcibbU2qb7T8O6hs_eO3K1uElQbgfAuBK80EybyaNzkk-kma6Z_5Cmz4KPGO_azLX8B30AQcg |
| CitedBy_id | crossref_primary_10_1155_2016_9636937 crossref_primary_10_3389_fimmu_2021_694573 crossref_primary_10_1038_nrdp_2015_15 crossref_primary_10_1371_journal_pone_0109256 crossref_primary_10_1016_j_clineuro_2018_09_023 crossref_primary_10_18632_oncotarget_9168 crossref_primary_10_1371_journal_pone_0176575 crossref_primary_10_3390_cancers14246218 crossref_primary_10_1016_j_ijmm_2015_07_002 crossref_primary_10_1155_2016_8215082 crossref_primary_10_3390_molecules27238422 crossref_primary_10_1038_s41598_020_67708_w crossref_primary_10_3389_fnins_2018_00977 crossref_primary_10_1007_s10495_014_0969_0 crossref_primary_10_1113_JP284166 crossref_primary_10_1186_s10020_021_00427_8 crossref_primary_10_1152_physiolgenomics_00056_2024 crossref_primary_10_4137_JCD_S11038 crossref_primary_10_1016_j_smrv_2014_07_003 crossref_primary_10_3760_cma_j_issn_0366_6999_20131439 crossref_primary_10_1038_s41467_023_41089_w crossref_primary_10_1155_2022_1438470 crossref_primary_10_1155_2018_3458615 crossref_primary_10_1007_s10495_013_0893_8 crossref_primary_10_1111_mmi_15164 crossref_primary_10_4062_biomolther_2015_097 crossref_primary_10_1002_mnfr_202101106 crossref_primary_10_1016_j_imlet_2017_08_009 crossref_primary_10_3389_fimmu_2017_01185 crossref_primary_10_1097_CM9_0000000000003352 crossref_primary_10_3389_fphys_2023_1108966 |
| Cites_doi | 10.1378/chest.123.3.695 10.1189/jlb.0703358 10.4049/jimmunol.170.4.1964 10.1016/j.yexcr.2006.08.022 10.1016/S0014-5793(02)03668-2 10.1007/978-1-4419-6706-0_6 10.1016/j.cellsig.2005.05.021 10.4049/jimmunol.176.2.957 10.1093/sleep/22.5.667 10.1182/blood-2002-02-0454 10.1164/rccm.200705-675OC 10.1042/bst0320461 10.1034/j.1600-065X.2003.00038.x 10.1016/j.resp.2010.11.001 10.1016/j.jaci.2007.10.003 10.1038/sj.cdd.4401320 10.4049/jimmunol.162.3.1692 10.1111/j.1365-2818.1993.tb03313.x 10.1084/jem.20031771 10.4049/jimmunol.174.6.3633 10.1182/blood.V93.9.3106.409k36_3106_3115 10.1007/s12026-008-8049-6 10.1183/09031936.00086608 10.1097/MOH.0b013e3283333b29 10.1074/jbc.M400063200 10.4049/jimmunol.167.7.3996 10.4049/jimmunol.176.2.1163 10.4049/jimmunol.157.7.3105 10.1016/S0014-5793(00)02324-3 10.1016/j.it.2011.01.001 10.1002/eji.200425091 10.1084/jem.20040624 10.1016/j.jacc.2008.05.002 10.1016/S0140-6736(02)09464-3 10.1074/jbc.273.14.8389 10.1042/bst0320489 10.1165/rcmb.2010-0025OC 10.3181/0811-MR-318 10.1186/1465-9921-10-24 10.1189/jlb.0406284 10.1189/jlb.68.1.158 10.4049/jimmunol.164.8.4286 10.4049/jimmunol.166.12.7486 10.1189/jlb.70.5.783 10.1182/blood.V99.2.672 10.1182/blood-2008-04-149575 10.1016/j.febslet.2010.05.061 10.1182/blood-2007-05-087833 10.1152/ajplung.00179.2006 10.1182/blood.V92.7.2495 10.1074/jbc.M313875200 10.1097/00024382-200204000-00005 10.1016/j.bbabio.2006.05.032 10.1042/CS20050178 10.1159/000074486 10.1067/msy.2000.107609 10.1002/ajh.21078 10.4049/jimmunol.172.11.7024 10.1016/0014-5793(95)00986-J |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2012 BioMed Central Ltd. 2012 Dyugovskaya et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright ©2012 Dyugovskaya et al.; licensee BioMed Central Ltd. 2012 Dyugovskaya et al.; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: COPYRIGHT 2012 BioMed Central Ltd. – notice: 2012 Dyugovskaya et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: Copyright ©2012 Dyugovskaya et al.; licensee BioMed Central Ltd. 2012 Dyugovskaya et al.; licensee BioMed Central Ltd. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/1479-5876-10-211 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1479-5876 |
| EndPage | 211 |
| ExternalDocumentID | oai_doaj_org_article_1282015d517c4897852c5602edf7b4cf PMC3543281 oai_biomedcentral_com_1479_5876_10_211 2862973061 A534280441 23088735 10_1186_1479_5876_10_211 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Germany |
| GeographicLocations_xml | – name: Germany |
| GroupedDBID | --- 0R~ 29L 2VQ 2WC 4.4 53G 5VS 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS EJD ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR IPNFZ ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RIG RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 3V. 7T5 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 -A0 ABVAZ ACRMQ ADINQ AFGXO AFNRJ C24 5PM PUEGO |
| ID | FETCH-LOGICAL-b716t-8c8810d956329db119abf186612b05bbdd0df45a9672329ce02c60ee9f302e1d3 |
| IEDL.DBID | RBZ |
| ISSN | 1479-5876 |
| IngestDate | Wed Aug 27 01:32:18 EDT 2025 Thu Aug 21 13:50:17 EDT 2025 Wed May 22 07:14:53 EDT 2024 Fri Jul 11 01:43:40 EDT 2025 Fri Jul 11 00:47:47 EDT 2025 Fri Jul 25 07:38:35 EDT 2025 Tue Jun 17 22:05:43 EDT 2025 Tue Jun 10 21:03:29 EDT 2025 Mon Jul 21 05:45:10 EDT 2025 Tue Jul 01 03:50:59 EDT 2025 Thu Apr 24 22:55:46 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b716t-8c8810d956329db119abf186612b05bbdd0df45a9672329ce02c60ee9f302e1d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| OpenAccessLink | http://dx.doi.org/10.1186/1479-5876-10-211 |
| PMID | 23088735 |
| PQID | 1268745988 |
| PQPubID | 43076 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_1282015d517c4897852c5602edf7b4cf pubmedcentral_primary_oai_pubmedcentral_nih_gov_3543281 biomedcentral_primary_oai_biomedcentral_com_1479_5876_10_211 proquest_miscellaneous_1315611928 proquest_miscellaneous_1273507939 proquest_journals_1268745988 gale_infotracmisc_A534280441 gale_infotracacademiconefile_A534280441 pubmed_primary_23088735 crossref_citationtrail_10_1186_1479_5876_10_211 crossref_primary_10_1186_1479_5876_10_211 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-10-22 |
| PublicationDateYYYYMMDD | 2012-10-22 |
| PublicationDate_xml | – month: 10 year: 2012 text: 2012-10-22 day: 22 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Journal of translational medicine |
| PublicationTitleAlternate | J Transl Med |
| PublicationYear | 2012 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | AS Saffar (1359_CR44) 2008; 121 SW Edwards (1359_CR12) 2004; 32 V Durand (1359_CR41) 2001; 167 V Brown (1359_CR3) 2009; 10 AD Kennedy (1359_CR49) 2009; 43 K Aoshiba (1359_CR34) 1999; 162 NA Maianski (1359_CR46) 2004; 11 M Pelletier (1359_CR27) 2002; 532 SJ Leuenroth (1359_CR31) 2000; 68 LW Thomas (1359_CR23) 2010; 584 NA Maianski (1359_CR42) 2002; 99 A Cross (1359_CR29) 2008; 111 L Dyugovskaya (1359_CR5) 2008; 177 A Carreras (1359_CR59) 2011; 175 D Petrin (1359_CR28) 2006; 18 AS Cowburn (1359_CR54) 2004; 34 DA Moulding (1359_CR26) 1998; 92 CD Garlichs (1359_CR1) 2004; 75 MJ Hebert (1359_CR40) 1996; 157 M Derouet (1359_CR25) 2004; 279 R Fudala (1359_CR55) 2007; 293 EMM Manders (1359_CR43) 1993; 169 HU Simon (1359_CR20) 2003; 193 MA Arruda (1359_CR50) 2006; 312 SC Frasch (1359_CR33) 1998; 273 S Francois (1359_CR53) 2005; 174 M Chopra (1359_CR4) 2009; 234 L Dyugovskaya (1359_CR9) 2011; 45 M Alvarado-Kristensson (1359_CR35) 2004; 199 V Witko-Sarsat (1359_CR14) 2011; 32 S Hannah (1359_CR6) 1995; 372 SR Walmsley (1359_CR7) 2005; 201 SJ Leuenroth (1359_CR30) 2000; 128 JB Klein (1359_CR36) 2000; 164 DA Moulding (1359_CR15) 2001; 70 SJ Gardai (1359_CR13) 2004; 279 C Akgul (1359_CR11) 2001; 487 1359_CR39 KI Mecklenburgh (1359_CR8) 2002; 100 ME Soriano (1359_CR17) 2010; 687 L Lavie (1359_CR58) 2009; 33 HR Luo (1359_CR52) 2008; 83 BJ van Raam (1359_CR22) 2008; 112 A Malhotra (1359_CR57) 2002; 360 E Er (1359_CR21) 2006; 1757 A Bar (1359_CR38) 2003; 123 LE Kilpatrick (1359_CR45) 2006; 80 G Fossati (1359_CR47) 2003; 170 VK Somers (1359_CR56) 2008; 52 M Derouet (1359_CR32) 2006; 176 SM Bianchi (1359_CR2) 2006; 110 P Weinmann (1359_CR18) 1999; 93 PK Epling-Burnette (1359_CR24) 2001; 166 NA Maianski (1359_CR19) 2004; 111 D Scheel-Toellner (1359_CR48) 2004; 32 DY Tamura (1359_CR10) 2002; 17 NA Maianski (1359_CR16) 2004; 172 M Cabrini (1359_CR51) 2010; 17 D Martinez (1359_CR37) 2006; 176 |
| References_xml | – volume: 123 start-page: 695 year: 2003 ident: 1359_CR38 publication-title: Chest doi: 10.1378/chest.123.3.695 – volume: 75 start-page: 828 year: 2004 ident: 1359_CR1 publication-title: J Leukoc Biol doi: 10.1189/jlb.0703358 – volume: 170 start-page: 1964 year: 2003 ident: 1359_CR47 publication-title: J Immunol doi: 10.4049/jimmunol.170.4.1964 – volume: 312 start-page: 3939 year: 2006 ident: 1359_CR50 publication-title: Exp Cell Res doi: 10.1016/j.yexcr.2006.08.022 – volume: 532 start-page: 164 year: 2002 ident: 1359_CR27 publication-title: FEBS Lett doi: 10.1016/S0014-5793(02)03668-2 – volume: 687 start-page: 97 year: 2010 ident: 1359_CR17 publication-title: Adv Exp Med Biol doi: 10.1007/978-1-4419-6706-0_6 – volume: 18 start-page: 479 year: 2006 ident: 1359_CR28 publication-title: Cell Signal doi: 10.1016/j.cellsig.2005.05.021 – volume: 176 start-page: 957 year: 2006 ident: 1359_CR32 publication-title: J Immunol doi: 10.4049/jimmunol.176.2.957 – ident: 1359_CR39 doi: 10.1093/sleep/22.5.667 – volume: 100 start-page: 3008 year: 2002 ident: 1359_CR8 publication-title: Blood doi: 10.1182/blood-2002-02-0454 – volume: 177 start-page: 544 year: 2008 ident: 1359_CR5 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200705-675OC – volume: 32 start-page: 461 year: 2004 ident: 1359_CR48 publication-title: Biochem Soc Trans doi: 10.1042/bst0320461 – volume: 193 start-page: 101 year: 2003 ident: 1359_CR20 publication-title: Immunol Rev doi: 10.1034/j.1600-065X.2003.00038.x – volume: 175 start-page: 164 year: 2011 ident: 1359_CR59 publication-title: Respir Physiol Neurobiol doi: 10.1016/j.resp.2010.11.001 – volume: 121 start-page: 492 year: 2008 ident: 1359_CR44 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2007.10.003 – volume: 11 start-page: 143 year: 2004 ident: 1359_CR46 publication-title: Cell Death Differ doi: 10.1038/sj.cdd.4401320 – volume: 162 start-page: 1692 year: 1999 ident: 1359_CR34 publication-title: J Immunol doi: 10.4049/jimmunol.162.3.1692 – volume: 169 start-page: 375 year: 1993 ident: 1359_CR43 publication-title: J Microsc doi: 10.1111/j.1365-2818.1993.tb03313.x – volume: 199 start-page: 449 year: 2004 ident: 1359_CR35 publication-title: J Exp Med doi: 10.1084/jem.20031771 – volume: 174 start-page: 3633 year: 2005 ident: 1359_CR53 publication-title: J Immunol doi: 10.4049/jimmunol.174.6.3633 – volume: 93 start-page: 3106 year: 1999 ident: 1359_CR18 publication-title: Blood doi: 10.1182/blood.V93.9.3106.409k36_3106_3115 – volume: 43 start-page: 25 year: 2009 ident: 1359_CR49 publication-title: Immunol Res doi: 10.1007/s12026-008-8049-6 – volume: 33 start-page: 1467 year: 2009 ident: 1359_CR58 publication-title: Eur Respir J doi: 10.1183/09031936.00086608 – volume: 17 start-page: 31 year: 2010 ident: 1359_CR51 publication-title: Curr Opin Hematol doi: 10.1097/MOH.0b013e3283333b29 – volume: 279 start-page: 21085 year: 2004 ident: 1359_CR13 publication-title: J Biol Chem doi: 10.1074/jbc.M400063200 – volume: 167 start-page: 3996 year: 2001 ident: 1359_CR41 publication-title: J Immunol doi: 10.4049/jimmunol.167.7.3996 – volume: 176 start-page: 1163 year: 2006 ident: 1359_CR37 publication-title: J Immunol doi: 10.4049/jimmunol.176.2.1163 – volume: 157 start-page: 3105 year: 1996 ident: 1359_CR40 publication-title: J Immunol doi: 10.4049/jimmunol.157.7.3105 – volume: 487 start-page: 318 year: 2001 ident: 1359_CR11 publication-title: FEBS Lett doi: 10.1016/S0014-5793(00)02324-3 – volume: 32 start-page: 117 year: 2011 ident: 1359_CR14 publication-title: Trends Immunol doi: 10.1016/j.it.2011.01.001 – volume: 34 start-page: 1733 year: 2004 ident: 1359_CR54 publication-title: Eur J Immunol doi: 10.1002/eji.200425091 – volume: 201 start-page: 105 year: 2005 ident: 1359_CR7 publication-title: J Exp Med doi: 10.1084/jem.20040624 – volume: 52 start-page: 686 year: 2008 ident: 1359_CR56 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2008.05.002 – volume: 360 start-page: 237 year: 2002 ident: 1359_CR57 publication-title: Lancet doi: 10.1016/S0140-6736(02)09464-3 – volume: 273 start-page: 8389 year: 1998 ident: 1359_CR33 publication-title: J Biol Chem doi: 10.1074/jbc.273.14.8389 – volume: 32 start-page: 489 year: 2004 ident: 1359_CR12 publication-title: Biochem Soc Trans doi: 10.1042/bst0320489 – volume: 45 start-page: 154 year: 2011 ident: 1359_CR9 publication-title: Am J Respir Cell Mol Biol doi: 10.1165/rcmb.2010-0025OC – volume: 234 start-page: 361 year: 2009 ident: 1359_CR4 publication-title: Exp Biol Med doi: 10.3181/0811-MR-318 – volume: 10 start-page: 24 year: 2009 ident: 1359_CR3 publication-title: Respir Res doi: 10.1186/1465-9921-10-24 – volume: 80 start-page: 1512 year: 2006 ident: 1359_CR45 publication-title: J Leukoc Biol doi: 10.1189/jlb.0406284 – volume: 68 start-page: 158 year: 2000 ident: 1359_CR31 publication-title: J Leukoc Biol doi: 10.1189/jlb.68.1.158 – volume: 164 start-page: 4286 year: 2000 ident: 1359_CR36 publication-title: J Immunol doi: 10.4049/jimmunol.164.8.4286 – volume: 166 start-page: 7486 year: 2001 ident: 1359_CR24 publication-title: J Immunol doi: 10.4049/jimmunol.166.12.7486 – volume: 70 start-page: 783 year: 2001 ident: 1359_CR15 publication-title: J Leukoc Biol doi: 10.1189/jlb.70.5.783 – volume: 99 start-page: 672 year: 2002 ident: 1359_CR42 publication-title: Blood doi: 10.1182/blood.V99.2.672 – volume: 112 start-page: 2046 year: 2008 ident: 1359_CR22 publication-title: Blood doi: 10.1182/blood-2008-04-149575 – volume: 584 start-page: 2981 year: 2010 ident: 1359_CR23 publication-title: FEBS Lett doi: 10.1016/j.febslet.2010.05.061 – volume: 111 start-page: 878 year: 2008 ident: 1359_CR29 publication-title: Blood doi: 10.1182/blood-2007-05-087833 – volume: 293 start-page: L364 year: 2007 ident: 1359_CR55 publication-title: Am J Physiol Lung Cell Mol Physiol doi: 10.1152/ajplung.00179.2006 – volume: 92 start-page: 2495 year: 1998 ident: 1359_CR26 publication-title: Blood doi: 10.1182/blood.V92.7.2495 – volume: 279 start-page: 26915 year: 2004 ident: 1359_CR25 publication-title: J Biol Chem doi: 10.1074/jbc.M313875200 – volume: 17 start-page: 269 year: 2002 ident: 1359_CR10 publication-title: Shock doi: 10.1097/00024382-200204000-00005 – volume: 1757 start-page: 1301 year: 2006 ident: 1359_CR21 publication-title: Biochim Biophys Acta doi: 10.1016/j.bbabio.2006.05.032 – volume: 110 start-page: 293 year: 2006 ident: 1359_CR2 publication-title: Clin Sci (Lond) doi: 10.1042/CS20050178 – volume: 111 start-page: 56 year: 2004 ident: 1359_CR19 publication-title: Acta Haematol doi: 10.1159/000074486 – volume: 128 start-page: 171 year: 2000 ident: 1359_CR30 publication-title: Surgery doi: 10.1067/msy.2000.107609 – volume: 83 start-page: 288 year: 2008 ident: 1359_CR52 publication-title: Am J Hematol doi: 10.1002/ajh.21078 – volume: 172 start-page: 7024 year: 2004 ident: 1359_CR16 publication-title: J Immunol doi: 10.4049/jimmunol.172.11.7024 – volume: 372 start-page: 233 year: 1995 ident: 1359_CR6 publication-title: FEBS Lett doi: 10.1016/0014-5793(95)00986-J |
| SSID | ssj0024549 |
| Score | 2.1841877 |
| Snippet | Prolonged neutrophil survival is evident in various cardiovascular and respiratory morbidities, in hypoxic conditions in-vitro and in patients with obstructive... Background Prolonged neutrophil survival is evident in various cardiovascular and respiratory morbidities, in hypoxic conditions in-vitro and in patients with... Doc number: 211 Abstract Background: Prolonged neutrophil survival is evident in various cardiovascular and respiratory morbidities, in hypoxic conditions... Background: Prolonged neutrophil survival is evident in various cardiovascular and respiratory morbidities, in hypoxic conditions in-vitro and in patients with... BACKGROUND: Prolonged neutrophil survival is evident in various cardiovascular and respiratory morbidities, in hypoxic conditions in-vitro and in patients with... Abstract Background Prolonged neutrophil survival is evident in various cardiovascular and respiratory morbidities, in hypoxic conditions in-vitro and in... |
| SourceID | doaj pubmedcentral biomedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 211 |
| SubjectTerms | Adult Analysis Apnea Apoptosis Bax protein Bax/Mcl-1 balance bcl-2-Associated X Protein - metabolism Care and treatment Case-Control Studies Cell survival Cell Survival - drug effects Cellular signal transduction Chronic obstructive pulmonary disease Confocal microscopy Demography Enzyme Activation - drug effects ERK 1/2 signaling Extracellular signal-regulated kinase Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors Extracellular Signal-Regulated MAP Kinases - metabolism Heart attacks Humans Hypoxia Hypoxia - complications Hypoxia - enzymology Hypoxia - pathology Inflammation Injuries Intermittent hypoxia Leukemia Leukocytes (neutrophilic) MAP Kinase Signaling System - drug effects Mcl-1 protein Medicine Microscopy Middle Aged Mitochondria Mitochondria - drug effects Mitochondria - metabolism Morbidity Myeloid Cell Leukemia Sequence 1 Protein Neutrophil mitochondrial apoptotic pathway Neutrophils - drug effects Neutrophils - pathology Obstructive Sleep Apnea Oxygen - pharmacology p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors p38 Mitogen-Activated Protein Kinases - metabolism p38MAPK signaling Phosphorylation Phosphorylation - drug effects Protein Transport - drug effects Proteins Proto-Oncogene Proteins c-bcl-2 - metabolism Respiratory distress syndrome Signal transduction Sleep Sleep apnea Sleep apnea syndromes Sleep Apnea, Obstructive - complications Sleep Apnea, Obstructive - enzymology Sleep Apnea, Obstructive - pathology Sleep disorders Statistical analysis Studies Translation Translocation Up-Regulation - drug effects Western blotting |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9RAEG5kD-JFfJt1lRYE8RAm_Uo64mVWdllcRkRc2FvTrzADQxKcGVn_gr_aqjyGCb4uXlPVk6TrPan-ipBXXGkRIlOp5b5Mpaxsqp13YHiyZNJDzHH4f8fiY35xJT9cq-uDUV_YE9bDA_cbNwP_CTFKBcUKLzXUPIp7iNI8hqpw0lfofSHmjcXUiLKnusSXyaJMFRj8-IFS57P9NfRAHCcHTU66rycBqsPx_9VbH4SraSvlQWw6v0fuDkklnfcvc5_civUDcnsxfDZ_SH6c2pvZwq9TRh22MvpIbd_HQeu4235t2uVqTTc7cBugeHRVU0SRwKP-kFFv6fJ729ysLLV1oI0bEGe_RbpZx9hS29bRvqVDYwhtKtoKvZh_uuz4zz5fshmn2CZi8eT7I3J1fvbl_UU6DGFIHZRS21R7rVkWoIwSvAyOsdK6ClHyGHeZci6ELFRS2TIvIDkrfcy4z7MYy0qAkFgQj8lR3dTxKaE-5lI5kbmgS1kFaQM4kGBVEbQL3PmEvJtIwrQ94IZBCOwpBazRoCANCtJAIQOCTMhsFJzxA8A5ztlYm67Q0flvVrzZrxjv9WfeU9SFyTN1F0BZzaCs5l_KmpDXqEkGnQc8mrfDGQjYH4ThMnMloBzMIEVNyMmEE4zeT8mjLprB6Wzg7jkOLyi1TsjLPRlXYiNdHZsd8hRCIShi-RceAUU9CJrD7zzp1Xv_2lCxQlgSKiHFRPEn-zKl1KtlB1sulBRcs-P_sZHPyB2g886E-Qk5As2PzyE73LoXnSP4CXp1Xg8 priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bixMxFA66gvgi3p11lQiC-DB0JpeZjAjSlV0Wl4qIC30LuY0tlJlx2y7rX_BXe8407e6g7muTtGnO9UtOvhDyhknFfchlapirUiFqkyrrLBieqHLhIOZY3O-YfClOzsTnqZzGDbdlLKvc-sTeUfvW4R75KGcFMrNXSn3sfqb4ahSersYnNG6TO0hdhuCrnF4BLgHgZ3s0qYpRLsoqlWD-6HsYvhk0uOO-GISmnsH_bz99LVANiyivRaXjB-R-TCfpeCP_h-RWaB6Ru5N4YP6Y_D40l6OJW6Q5tVjE6AI1mwoO2oT16rztZvMFXa7BYYDK0XlDkT8CL_lDLr2is19dezk31DSetjZyzV4EulyE0FHTNcG8p7EkhLY17biajL-e9v2Pvp3mI0axQMTgnfcn5Oz46PunkzQ-v5BaAFGrVDml8swDgOKs8hYW2Nga-fFyZjNprfeZr4U0VVFCWla5kDFXZCFUNc9YyD1_SvaatgnPCXWhENLyzHpVidoL48F1eCNLr6xn1iXkw0ASuttQbWgkvx62gE5oFKRGQWqAMCDIhIy2gtMuUpvjCxsL3UMcVfxjxLvdiO1v_b_vIerCYE79B-35Dx3tW0OYh1RKepmXTiiA5pI5SCZZ8HVphasT8hY1SaPbgKk5E28_wPogAZceSw5AMIPkNCEHg55g7m7YvNVFHd3NUl8ZR0Je75pxJJbQNaFdY5-SS6RDrG7owwHOg6AZfM-zjXrv_jZgVQhIXCakHCj-YF2GLc181hOWcyk4U_n-zVN_Qe7BErLeONkB2QOdDi8h41vZV71Z_wG1iVTE priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bi9NAFB5kBfFFvBtdZQRBfIhN5pJMRJGu7LK4VEQs7Nswt9hCSGov0v0L_mrPSdPuRqsvvnbOJOmce3LOdwh5waTiPqQyNswVsRCliZV1FhRPFKlw4HMsvu8YfcpOx-LjuTy_bI_uDnCxN7XDeVLjefV6_f3iPSj8u1bhVTZIRV7EEtQabQrDRt_r4JdyHOQwEuoSeU-2wfCOevvRcs8Vfut-r3pOq8X2_9OCX3Fh_fLKK_7q5Da51QWadLiRjDvkWqjvkhuj7lP6PfLzyKwHI1fFKbVY3ugCNZvaDlqH1XLezCbTii5WYEpAGOm0pogsge3_EGUv6eRi1qynhpra08Z2KLQ_Al1UIcyomdXBvKFdsQhtSjrjajT8fNbSH385SweMYumIwW74-2R8cvz1w2ncDWaILaRXy1g5pdLEQ2rFWeFtmhbGloiclzKbSGu9T3wppCmyHAK2woWEuSwJoSh5wkLq-QNyUDd1eESoC5mQlifWq0KUXhgPRsUbmXtlPbMuIm97nNCzDQiHRljs_gpoqEZGamSkhuQGGBmRwZZx2nWg5zh7o9Jt8qOyPTte7XZs7_V32iOUhd4ztT8082-603wNAQAEWdLLNHdCQdIumYMwkwVf5la4MiIvUZI0ijg8mjNdXwScD0Jz6aHkkCImELZG5LBHCYbA9Ze3sqi3egR3z3CgQaFURJ7vlnEnFtfVoVkhTc4lAiUW_6DhkOgDoxlc5-FGvHd_G7JYcFVcRiTvCX7vXPor9XTSQplzKThT6eP_4_ITchOOmLXKyw7JAch8eAqx4tI-a03AL9-YZUk priority: 102 providerName: Scholars Portal |
| Title | Bax/Mcl-1 balance affects neutrophil survival in intermittent hypoxia and obstructive sleep apnea: effects of p38MAPK and ERK1/2 signaling |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/23088735 https://www.proquest.com/docview/1268745988 https://www.proquest.com/docview/1273507939 https://www.proquest.com/docview/1315611928 http://dx.doi.org/10.1186/1479-5876-10-211 https://pubmed.ncbi.nlm.nih.gov/PMC3543281 https://doaj.org/article/1282015d517c4897852c5602edf7b4cf |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bi9NAFB50F8QX8b7RtYwgiA-hmVsyEV9a6bK4dFmKC8WXYW6hhZAE28r6F_zVnknT7mZdffGlD50zucy5Z875BqF3VEjmPBGxpjaPOS90LI01oHg8J9yCzzHhe8f0PD295F_mYn4Nk3NrB5_IdEh4lscClDZYDBraeA8pz3g4pmE2_naNqyfaUHdPvduSvOMKt3rby55LapH7_7TPNxxUv3jyhjc6eYwedWEkHm35_gTd89VT9GDabZQ_Q7_G-mo4tWVMsAnFi9Zjva3cwJXfrL_XzWJZ4tUGDAWIGl5WOOBGhOZ-iKHXePGzqa-WGuvK4dp0GLM_PF6V3jdYN5XXH3FXCoLrAjdMTkcXZy39ZHZGhhSHwhAdet2fo8uTydfPp3F37EJsIHlax9JKSRIHiROjuTOE5NoUARePUJMIY5xLXMGFztMMwrHc-oTaNPE-L1hCPXHsBTqo6sofIWx9yoVhiXEy54Xj2oHJcFpkThpHjY3Qpx4nVLOF2FAB9Lo_AvqnAiNVYKSC1AUYGaHhjnHKdpDm4WSNUrWpjUzvmPFhP2N3r7_TjoMs9J6p_QOkU3V6rcC9QwglnCCZ5RJSckEtBJHUuyIz3BYReh8kSQVzAY9mddf1AOsTgLfUSDBIABMISiN03KMENbf94Z0sqs7MrODuaTiuIJcyQm_3w2FmKJ2rfL0JNBkTAQYx_wcNgzQeGE3hOi-34r1_bchRwRExEaGsJ_i9demPVMtFC1TOBGdUklf_x-XX6CEsMW2Vlx6jA5B5_wYiwbUZoPvZPBugw_Hk_GI2aL-nwO-Uy0FrHH4DL4FcDA |
| linkProvider | BioMedCentral |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtQwELVKKwEviDsLBYwEQjxEG98SB4HQFlq1bLeqqlbqm-tb6EqrJHR3of0FPoZvZJxN2kZA3_q6trOOZ3xmJh6fQeg1FZI5T0Skqc0iznMdSWMNbDyeEW7B5pjwvWO0k2we8K-H4nAJ_W7vwoS0yhYTa6B2pQ3fyPuEJoGZPZPyU_U9ClWjwulqW0JjoRZDf_YTQrbpx60vIN83lG6s73_ejJqqApGB2GAWSSsliR3EBYxmzhCSaZMH2jdCTSyMcS52ORc6S1LwNjLrY2qT2PssZzH1xDF47g20whm4CstoZW19Z3fvgt0Pwq32MFQmfcLTLBIAOAHtaKhS1LlVP-kYw7pmwN-W4ZJp7KZtXrKDG3fRncaBxYOFxt1DS764j26OmiP6B-jXmj7tj-wkItiEtEnrsV7kjODCz2cnZXU8nuDpHCAKlByPCxwYKwKtAHjvM3x8VpWnY4114XBpGnbbHx5PJ95XWFeF1-9xk4SCyxxXTI4Gu8O6__rekPQpDikpOtyyf4gOrkU0j9ByURb-CcLWJ1wYFhsnM547rh2AldMiddI4amwPfehIQlULcg8V6La7LaCFKghSBUEqCJpAkD3UbwWnbEOmHmp6TFQdVMnkHyPenY9o_-v_fdeCLnTmVP9QnnxTDaIocCzAeRNOkNRymaVSUAvuK_UuTw23eQ-9DZqkAlDB1Kxu7lvA-gTKLzUQDELPGNzhHlrt9ASAsd3mVhdVA3BTdbEde-jVeXMYGZL2Cl_OQ5-UiUDAmF3RhxHw4CHMgOc8Xqj3-WtDdAwmkIkeSjuK31mXbksxPq4p0pngjEry9Oqpv0S3NvdH22p7a2f4DN2G5aT1RqWraBn02z8Hf3NmXjSbHKOj68aVP0BKklk |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELemIU28IL4JDDASEuIhNHHsxEG8tLBqUDpNiEkTPFj-Cq2Ikmhr0fgX-Ku5S9PSwOCFtyg-58N3_vkuufuZkKdMyMT5WISa2TzkvNChNNbAxON5zC2sOQa_d0yP0sMT_u5UnO6Qz-tamG4EAYIQqsvug9j6P_OL7Zr0sgVyOLBfB40rVvNfpoOYZ3koYJYjxDCs-72SIdEUhvKjT7-I-ETrG2-k1_8wL7nCb8XwZW8Na6n-_wT0rRWtn225tXyNr5Nrnd9JhytDuUF2fHWT7E27N75Ffoz0xWBqyzCmBrMdrad6lepBK79cnNXNbF7S8yUgC9gmnVcUiSaQDQCc7gWdfW_qi7mmunK0Nh0p7TdPz0vvG6qbyuuXtMsdoXVBm0ROh8eTVv7gwyQeMIqZJBqL42-Tk_HBx9eHYbdPQ2gg2lqE0koZRw4irYTlzsRxrk2BRHoxM5EwxrnIFVzoPM3Af8utj5hNI-_zIomYj11yh-xWdeXvEWp9yoVJIuNkzgvHtQOMcVpkThrHjA3Iq54mVLPi5FDIkt1vAeNQqEiFilQQ64AiAzJYK07ZjgMdt-IoVRsLyfSSHs83Pdb3-rvsCG2h90ztifrsi-qAQIE_AD6XcCLOLJcQwwtmwetk3hWZ4bYIyDO0JIX4gratuzIJGB9k6lJDkUDEGIEXG5D9niTggu03r21RdbPqHO6e4v4GuZQBebJpxp6Ya1f5eokyWSKQNzH_h0wCcT8omsF17q7Me_PaENTCypWIgGQ9w--NS7-lms9aZvNE8ITJ-P7_afkx2Tt-M1bv3x5NHpCrMNqsncdsn-yC-fuH4EUuzKMWDX4CKnduZA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bax%2FMcl-1+balance+affects+neutrophil+survival+in+intermittent+hypoxia+and+obstructive+sleep+apnea%3A+effects+of+p38MAPK+and+ERK1%2F2+signaling&rft.jtitle=Journal+of+translational+medicine&rft.au=Dyugovskaya%2C+Larissa&rft.au=Polyakov%2C+Andrey&rft.au=Cohen-Kaplan%2C+Victoria&rft.au=Lavie%2C+Peretz&rft.date=2012-10-22&rft.pub=BioMed+Central+Ltd&rft.issn=1479-5876&rft.eissn=1479-5876&rft.volume=10&rft.issue=1&rft.spage=211&rft.epage=211&rft_id=info:doi/10.1186%2F1479-5876-10-211&rft.externalDBID=n%2Fa&rft.externalDocID=oai_biomedcentral_com_1479_5876_10_211 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon |